Monte Rosa Therapeutics (GLUE) Tax Provisions (2023 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Tax Provisions of $100000.0 for Q1 2026, down 87.83% year-over-year from $822000.0 in Q1 2025, and up 69.49% quarter-over-quarter from $59000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Tax Provisions (2023 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Tax Provisions fell 87.83% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at -$1.8 million (up 87.0% YoY), while the FY2025 annual figure was -$1.1 million, up 92.55% from the prior year.
- Tax Provisions for Q1 2026 stood at $100000.0, up from $59000.0 in the prior quarter.
- The five-year high for Tax Provisions was $1.2 million in Q2 2025, with the low at -$15.1 million in Q4 2024.
- The 4-year median for Tax Provisions is $100000.0 (2024), against an average of -$1.3 million.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions plunged 68686.36% in 2024, then jumped 722.0% in 2025.
- Monte Rosa Therapeutics' Tax Provisions stood at -$22000.0 in 2023, then slumped by 68686.36% to -$15.1 million in 2024, then soared by 100.39% to $59000.0 in 2025, then surged by 69.49% to $100000.0 in 2026.
- Business Quant data shows GLUE's Tax Provisions at $100000.0 in Q1 2026, $59000.0 in Q4 2025, and -$3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 208,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 208,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | -3.18 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 822,000.00 |
| Dec 31, 2024 | -15.13 Mn |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | 170,000.00 |
| Jun 30, 2023 | 190,000.00 |